Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial

被引：37

作者：

Douillard, J. ^{[1
]}

Siena, S. ^{[2
]}

Cassidy, J. ^{[3
]}

Tabernero, J. ^{[4
]}

Burkes, R. ^{[5
]}

Barugel, M. E. ^{[6
]}

Humblet, Y. ^{[7
]}

Cunningham, D. ^{[8
]}

Wolf, M. ^{[9
]}

Gansert, J. L. ^{[9
]}

机构：

[1] Site Hosp Nord, Ctr Rene Gauducheau, Nantes, France

[2] Osped Niguarda Ca Granda, SC Div Oncol Falck, Milan, Italy

[3] Univ Glasgow, Dept Oncol, Canc Res UK, Glasgow, Lanark, Scotland

[4] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[5] Mt Sinai Hosp, Dept Oncol, Toronto, ON M5G 1X5, Canada

[6] Hosp Gastroenterol, Buenos Aires, DF, Argentina

[7] Univ Catholique Louvain, Ctr Canc, B-1200 Brussels, Belgium

[8] NHS Fdn Trust, London, England

[9] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 03期

关键词：

D O I：

10.1016/S1359-6349(09)72039-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：6 / 6

页数：1